Loading...
XNAS
XENE
Market cap2.21bUSD
May 30, Last price  
28.85USD
1D
-0.65%
1Q
-22.07%
Jan 2017
274.68%
IPO
141.02%
Name

Xenon Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
24.60%
Rev. gr., 5y
97.87%
Revenues
0k
6,918,00014,308,00027,356,00028,370,00015,577,0001,803,000311,00006,829,00032,166,00018,437,0009,434,00000
Net income
-234m
L+28.48%
-11,992,000-4,301,00012,032,00013,018,000-15,752,000-22,997,000-30,704,000-34,497,000-41,595,000-28,837,000-78,882,000-125,373,000-182,393,000-234,330,000
CFO
-181m
L+24.81%
-13,689,00045,573,000-3,322,000266,000-18,103,000-19,567,000-28,726,000-34,724,000-4,632,000-48,124,000-69,502,000-98,430,000-145,327,000-181,389,000
Earnings
Aug 06, 2025

Profile

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
URL
https://www.xenon-pharma.com/
IPO date
Oct 17, 2014
Employees
203
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,434
-48.83%
Cost of revenue
279,298
381,566
244,344
Unusual Expense (Income)
NOPBT
(279,298)
(381,566)
(234,910)
NOPBT Margin
Operating Taxes
4,089
292
118
Tax Rate
NOPAT
(283,387)
(381,858)
(235,028)
Net income
(234,330)
28.48%
(182,393)
45.48%
(125,373)
58.94%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,083
353,487
278,471
BB yield
-0.40%
-11.47%
-11.67%
Debt
Debt current
1,369
1,299
488
Long-term debt
16,661
20,507
20,382
Deferred revenue
Other long-term liabilities
26,575
(509)
Net debt
(608,875)
(909,068)
(699,899)
Cash flow
Cash from operating activities
(181,389)
(145,327)
(98,430)
CAPEX
(5,617)
(2,894)
Cash from investing activities
165,000
(117,170)
(296,003)
Cash from financing activities
12,130
353,522
278,471
FCF
(282,758)
(383,798)
(239,412)
Balance
Cash
626,905
638,082
592,087
Long term investments
292,792
128,682
Excess cash
626,905
930,874
720,297
Stockholders' equity
555,754
771,157
579,389
Invested Capital
208,164
167,667
152,034
ROIC
ROCE
EV
Common stock shares outstanding
77,895
66,889
60,542
Price
39.20
-14.89%
46.06
16.81%
39.43
26.22%
Market cap
3,053,470
-0.89%
3,080,908
29.06%
2,387,177
75.15%
EV
2,444,595
2,171,840
1,687,278
EBITDA
(279,298)
(378,025)
(233,286)
EV/EBITDA
Interest
5,512
Interest/NOPBT